Search

SLV319

SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.

PR-15

PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

Brolucizumab

[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]

Inetetamab

It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

Clevidipine

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Phthalylsulfathiazole

It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

PR-104

Rosmarinic acid

Sulthiame

Phentolamine

Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...